Partnering with Industry
Research and Development Partnering Opportunities in Life Sciences
| Company | Scope | Brief Description | Areas of Interest |
|---|---|---|---|
| Abbvie Research & Innovation | Preclinical | The Compound Toolbox provides compounds or probes for use in preclinical research across multiple therapeutic areas at no charge. Requests are submitted through the Open Innovation Portal and a signed MTA is required before compounds will be shipped. | Immunology Oncology Neurology Hepatology Cystic Fibrosis |
| Preclinical and clinical | The Investigator-Initiated Study (IIS) Program provides research support for academic and community-based physicians and researchers. Proposals are evaluated based on scientific merit, alignment with Abbvie’s areas of interest, and availability of funding. A research agreement must be signed prior to financial support being granted. Proposals are accepted according to a schedule with the exception of preclinical studies in pre-registration compounds and clinical studies in Hepatology/HCV and Oncology, which are done on a rolling basis. Proposals can be submitted here. | Biotherapeutics Hepatology Immunology Men's Health Neuroscience Oncology Pancreatology Renal Women's Health | |
| Amgen Academic Collaborations | Preclinical | Amgen will provide materials for non-human studies based upon a research study plan submitted by the investigator. A research agreement will be signed between Amgen and investigator’s institution. | None specified |
| Astellas Investigator Sponsored Research | Clinical | Investigators can submit requests for funding and/or drug support via the Investigator Sponsored Research Portal. | None specified |
| AstraZeneca Partnering | Preclinical and clinical | AstraZeneca Externally Sponsored Research will support interventional clinical research (Phase I-IV), observational research, and non-clinical research. Investigators can submit ESR proposals through ES2ROS. | Cardiovascular & metabolic diseases Gastrointestinal Infection Neuroscience Oncology Respiratory, inflammation & autoimmunity |
| Preclinical and clinical | AstraZeneca's Open Innovation platform provides for collaboration across all stages of drug discovery. This includes access to compound libraries and new molecular profiling capabilities. Investigators should access the specific program of interest through the Open Innovation website for proposal submission details. | None specified | |
| Bayer Pharmaceuticals Partnering | Preclinical and clinical | Bayer supports web-based crowd-sourcing initiatives to offer grants to support specific projects. This includes Grants4Targets, Grants4Leads, Grants4Apps, and PartnerYourAntibodies. Bayer's research incubator, CoLaborator, offers laboratory space and access to Bayer resources. | Targets: PartnerYourAntibodies: |
| Biogen Medical Research | Clinical | Biogen supports medical research in areas of interest relevant to their portfolio. Study proposals are submitted through the online submission portal. | Multiple sclerosis Hemophilia Biosimilars |
| Boehringer Ingelheim Pharmaceuticals Investigator Initiated Studies | Clinical | Boehringer Investigator Initiated Studies (IIS) Program supports research for products and therapeutic areas of interest through clinical and health outcomes research. Investigators can submit proposals through the online submission site. | Respiratory Cardiovascular Oncology Endocrinology |
| Bristol-Myers Squibb Investigator-Sponsored Research | Preclinical and clinical | Bristol-Myers Squibb Investigator-Sponsored Research (ISR) Program supports clinical, non-interventional, and non-clinical research. In addition, investigators may also submit proposals related to Pediatric Research. | Clinical and Non-Interventional: Priority given to: Cardiovascular/metabolics Neuroscience Cancer Immunology Virology |
| Celgene Investigator-Initiated Trials | Clinical | Celgene Investigator-Initiated Trials Program is interested in funding research that utilizes Celgene compounds to further advance a specific drug. Investigators can submit ideas through the Celgene MATRIX system. | None specified |
| Eisai Investigator Initiated Studies Program | Pre-clinical, Prospective clinical and Retrospective Studies | Eisai's Investigator Initiated Studies (IIS) Program provides research grants via clinical supplies and/or funding for projects that align with Eisai's areas of interest or products. Investigators can begin submitting proposals by selecting the appropriate therapeutic area. | Epilepsy Breast cancer Hepatocellular Carcinoma Renal cell cancer Soft tissue sarcoma Thyroid cancer |
| Eli Lilly Scientific Innovation | Clinical | Lilly Investigator Initiated Research (IIR) involves Lilly products that have been approved for marketing for at least one indication. | Immunology Diabetes Oncology Neurodegenerative diseases Headache Pain |
| Genzyme Partnering | Preclinical and clinical | Genzyme is interested in considering proposals at any stage of development. | None specified |
| Gilead Investigator Sponsored Research | Clinical | Gilead Investigator Sponsored Research (ISR) provides grants in therapeutic areas of interest. Investigators can submit proposals through the online application form. | HIV/AIDS Liver disease Hematology/oncology Cardiovascular Inflammation/respiratory |
| GlaxoSmithKline Investigator-Sponsored Studies Program | Clinical | Through the Investigator-Sponsored Studies Program, GSK may provide funding and/or materials to investigators seeking support. Proposals may be submitted through the registration portal. Oncology- and HIV-specific proposals are handled via other mechanisms. | None specified |
| Johnson & Johnson Innovation | Preclinical and clinical | J&J Innovation Centers are interested in exploring early stage therapeutic and vaccine technologies. Investigators can submit ideas through the J&J Innovation Centers page. Note that all ideas must have a patent filing. | Pharmaceuticals: Medical Devices: Consumer: Global Public Health: |
| Merck KGaA Open Innovation Portal | Preclinical and clinical | EMD Serono Open Innovation Portal provides access to several programs, including those that provide open source access to antibodies and compounds, a screening library, and open lab space. To submit a compound through the Open Compound Sourcing Program, a Participation and Material Supply Agreement must be signed by the institution. To access the Mini Library, an EMD Serono Mini Library Agreement will be required if your application is approved. | None specified |
| Preclinical and clinical | EMD Serono Grant for Growth Innovation (GGI) Program provides support for projects that have the potential to advance understanding in the field of growth. Proposals are accepted during an annual RFP. Applicants can begin submitting a proposal by following the process described. | Growth (in general) Priority given to: | |
Preclinical and clinical | Novartis Investigator Initiated Trials (ITTs) should address meaning scientific and/or clinical objectives supported by valid scientific designs. Investigators may request support in the form of funding, drug, or both. | None specified | |
Preclinical and clinical | Novartis Pharmaceuticals provides opportunities in several areas, including pharmaceuticals in development that have reached proof of concept in humans, new technology in drug delivery or in process scale-up/development, new technology that can improve an established, validated manufacturing process, and joint regional commercialization efforts for marketed pharmaceuticals. Opportunities can be submitted using the online submission form. Opportunities may also be submitted for marketed or late-stage oncology diagnostics or companion diagnostics. | None specified | |
Preclinical | Novartis Institutes for BioMedical Research (NIBR) provides opportunities for early-stage compounds and technologies in Novartis’ areas of interest. Proposals can be submitted via the online submission form. | None specified | |
Preclinical and clinical | Sandoz, the generic pharmaceuticals division of Novartis, provides opportunities to partner in generic and biosimilar medicine. Proposals should be emailed to Sandoz. | None specified | |
Preclinical and clinical | Alcon, which provides leading eye care products, accepts opportunities for enhance its portfolio of pharmaceutical and surgical products. Proposals should be emailed to Alcon. | None specified | |
Preclinical and clinical | Pfizer R&D’s Investigator-Initiated Research Program may provide funding and/or drug for preclinical or clinical studies. Requests can be submitted through the submission website. For investigators interested in obtaining a Pfizer pure substance compound through the Compound Transfer Program, a Compound Transfer Agreement (CTA) will need to be executed. Initial requests should be submitted through the INSPIIRE portal for processing and approval. | None specified | |
Preclinical and clinical | The Regeneron Investigator-Initiated Study (IIS) Program provides support for studies focused on Regeneron products and drug or for preclinical studies focused on Regeneron’s areas of interest. Investigators may also access Regeneron therapeutics candidates, animal models, cell lines and other technologies through external academic research collaborations. | IIS: Ophthalmic neovascular diseases Cardiovascular Inflammatory diseases Auto-immune conditions External collaborations: None specified | |
Preclinical and clinical | Scientific Project Support provides funding for general research, translational research, other research or development projects, and/or other initiatives for academic institutions. Grants are subject to the Genentech Letter of Agreement which is signed after the application is approved. Investigators can apply for funding. Investigators may also request reagents and mice from Genentech using the MTA Request Form. | Scientific Project Support: None specified but Genentech may post Call for Grant Notifications (CGN) to request projects in specific areas. | |
Preclinical and clinical | Sanofi Investigator Sponsored Studies (ISS) support preclinical and clinical studies aimed at the advancement of disease knowledge and potential treatments in therapeutic areas of interest to Sanofi US. | Diabetes Vaccines & infectious diseases Rare diseases Immunology & inflammation Cardiovascular & metabolism Multiple sclerosis Cancer Neurodegenerative diseases Animal health | |
| Preclinical and clinical | Shire’s Investigator-Initiated Research (IIR) Program supports clinical and scientific investigation into the understanding of diseases of interest to Shire or relating to Shire’s products. | Behavioral health Hematology Gastrointestinal disorders Ophthalmic diseases Hypoparathyroidism Hereditary angioedema (HAE) Gaucher disease Fabry disease Hunter syndrome Adrenal insufficiency | |
Preclinical and clinical | Investigator Initiated Sponsored Research (IISR) supports scientific advances in medicine and increasing understanding of important diseases related to Takeda’s compounds and therapeutic areas of interest. Support can be in the form of study drug and/or funding. Submit IISR requests. | Oncology Gastrointestinal Central nervous system Specialty cardiovascular Vaccines | |
Preclinical and clinical | Vertex Investigator-Initiated Studies supports the advancement of scientific and medical knowledge about cystic fibrosis through funding support or providing study drug. Nonclinical studies using Vertex compounds for in vitro assays or in vivo models are also eligible for support. Investigators can submit proposals through the Vertex application website. Investigators may request compounds for non-clinical studies by sending a request. | Cystic fibrosis Fibrotic disorders Neurodegenerative diseases Oncology Orphan diseases |